Skip to main content

Market Overview

Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients

Share:
Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
  • Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors.
  • Data will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021.
  • The subset of patients includes those who were heavily pretreated with estrogen-blocking agents and chemotherapy with an average of 3 prior lines of therapy in the metastatic setting and had tumor progression on a CDK 4/6 inhibitor before receiving enobosarm.
  • Enobosarm treatment in evaluable patients who had progressed following treatment with an estrogen-blocking agent and CDK 4/6 inhibitor (palbociclib) resulted in a clinical benefit rate at 24 weeks of 50% and a best objective tumor response of 30%, including two complete responses and one partial response.
  • The overall mean radiographic progression-free survival for the 9mg dose was ten months.
  • The 9mg dose of enobosarm was selected for the Phase 3 ARTEST study anticipated to start in June.
  • Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in AR+ER+HER2- metastatic breast cancer.
  • Price Action: VERU stock moved 26.4% higher at $11 during the premarket trading session on the last check Wednesday.
 

Related Articles (VERU)

View Comments and Join the Discussion!

Posted-In: breast cancer BriefsBiotech News Health Care Small Cap General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com